<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven A Curley, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keith E Stuart, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan M Schwartz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Carithers, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Klaudia U Hunter, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher G Willett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H361319942">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of cirrhosis. The two factors that are most important in determining a patient's prognosis and potential treatment options are the tumor mass and the patient's hepatic reserve.
        </p>
        <p>
         Treatment options are divided into potentially curative surgical therapies (ie, resection and orthotopic liver transplantation) and nonsurgical therapies, some of which may provide long-term disease control (ie, radiofrequency ablation [RFA]; microwave ablation [MWA]; percutaneous ethanol injection [PEI]; cryoablation; irreversible electroporation; transarterial embolization, which includes bland embolization, chemoembolization, and radioembolization; radiation therapy; and systemic therapy). In general, for most patients with HCC limited to the liver who are not candidates for surgical resection or liver transplantation, locoregional liver-directed therapies are preferable to systemic therapy.
        </p>
        <p>
         This topic review will cover transarterial embolization and RT. Other ablative nonsurgical therapies (RFA, MWA, PEI, cryoablation, microwave and laser coagulation, irreversible electroporation) are discussed elsewhere, as are resection, liver transplantation, and systemic therapy for HCC, as well as an overview of treatments for HCC. (See
         <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361319949">
         <span class="h1">
          TREATMENT ALGORITHMS AND GENERAL APPROACH TO THE PATIENT WITH LOCALIZED DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         An algorithmic approach to the treatment of HCC is shown in the figure  (
         <a class="graphic graphic_algorithm graphicRef57014" href="/z/d/graphic/57014.html" rel="external">
          algorithm 1
         </a>
         ). The suggested approach is useful for conceptualizing the various treatment options that are available for individual patients, but it may not be applicable in all settings. Alternative algorithms are available from other groups, such as the one that is used by the Barcelona Clinic Liver Cancer group  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. However, attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments and indications for various treatments are evolving rapidly. Furthermore, therapeutic approaches tend to vary based upon underlying liver function, available expertise, and variability in the criteria for hepatic resection and orthotopic liver transplantation. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Treatment algorithms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H457341302">
         <span class="h1">
          IMPORTANCE OF MULTIDISCIPLINARY CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We strongly urge that patients with HCC (especially localized HCC) be referred to specialized centers of excellence with multidisciplinary expertise so that the entire range of potentially available treatments can be offered, along with assessment, monitoring, and treatment of the underlying liver disease. The wide variety of treatments for HCC are offered by different specialties: surgery, radiation oncology, medical oncology, and interventional radiology. Multidisciplinary evaluation and planning typically result in more thoroughly vetted recommendations and are less likely to result in a recommendation for a procedure for which a single provider has expertise but that may not represent the optimal therapy for an individual patient.
        </p>
        <p>
         The majority of patients with HCC have underlying liver disease. Patients who undergo any form of therapy for HCC are at high risk for progression to liver failure because of their underlying liver disease, and proper monitoring, assessment, and treatment of the underlying liver disease may have a major impact on long-term survival. Multidisciplinary care has been shown to improve survival in patients with HCC [
         <a href="#rid2">
          2,3
         </a>
         ]. The comprehensive care of patients with cirrhosis includes antiviral therapy for hepatitis B and C virus, immunization against hepatitis A and B virus (if indicated), regular surveillance for HCC with abdominal imaging, and endoscopic screening and surveillance for varices. (See
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2381976013">
         <span class="h1">
          ASSESSING RESPONSE TO LOCOREGIONAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antitumor effect of many nonsurgical locoregional treatment modalities for HCC is not accurately reflected by conventional bidimensional tumor measurements performed on radiographic studies. Accurate assessment of response following nonsurgical locoregional treatment requires evaluation of residual tumor enhancement after therapy as based on the American College of Radiology's Liver Reporting and Data System (LI-RADS) treatment response algorithm after locoregional therapies for HCC  (
         <a class="graphic graphic_algorithm graphicRef130552" href="/z/d/graphic/130552.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid4">
          4,5
         </a>
         ]. The most important feature of the treatment response algorithm is persistent lesion contrast enhancement and washout. For some patients, the effectiveness of therapy may also be monitored by serial assay of tumor markers such as alpha fetoprotein (AFP). These same characteristics are used for early detection of residual/recurrent tumor and new areas of tumor involvement. (See
         <a class="medical medical_review" href="/z/d/html/83809.html" rel="external">
          "Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer"
         </a>
         .)
        </p>
        <p>
         Assessment of treatment response after nonsurgical local therapies should be performed with multiphase (including arterial, portal venous, and delayed phase imaging), contrast-enhanced, cross-sectional imaging (computed tomography [CT] with iodinated contrast or magnetic resonance imaging [MRI] with gadolinium-based agents). MRI is the preferred imaging modality with a sensitivity and specificity for lesion detection of 88 and 94 percent, respectively [
         <a href="#rid6">
          6
         </a>
         ]. As tumor enhancement characteristics post-therapy are essential in assessment for tumor viability [
         <a href="#rid4">
          4
         </a>
         ], contrast should be administered unless there are contraindications. Ordering the examinations specifically for HCC post-treatment surveillance imaging will ensure an appropriate imaging protocol will be used. Patients with iodinated contrast allergies should be routed to MRI and those with gadolinium allergies to CT. Preexisting kidney impairment is not considered a contraindication for contrast-enhanced MRI [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         We recommend dynamic (contrast-enhanced) cross-sectional imaging with either CT or MRI one to three months after nonsurgical locoregional therapy for HCC. Using the LI-RADS treatment response algorithm, tumors are categorized as viable, nonviable, or equivocal [
         <a href="#rid4">
          4,8
         </a>
         ]. The absence of contrast uptake within the tumor reflects nonviable tumor, while the persistence of contrast uptake indicates persistent disease, referred to as viable. If a tumor has enhancement atypical for treatment, it is deemed equivocal. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement within the tumor or the development/growth of enhancing soft tissue along the periphery of the treated lesion. (See
         <a class="medical medical_review" href="/z/d/html/83809.html" rel="external">
          "Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Response after locoregional therapy'
         </a>
         .)
        </p>
        <p>
         We typically reimage every three months for two years. After two years with no evidence of disease recurrence, we revert back to standard HCC surveillance with cross-sectional imaging and AFP assay every six months. At many institutions, cross-sectional imaging every six months is continued beyond the two-year cutoff, given the continued elevated risk for HCC in these patients. However, after two years with no evidence of disease recurrence, other institutions revert back to standard HCC surveillance with ultrasound and AFP assay every six months, especially for low-risk patients who are not transplant candidates. The use of ultrasound in this situation is controversial, and many believe that the risk remains sufficiently high that periodic cross-sectional imaging should be continued beyond two years. We agree with this approach. (See
         <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">
          "Surveillance for hepatocellular carcinoma in adults", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1442106415">
         <span class="h1">
          PATIENTS WITHOUT PVTT OR A LARGE INTRAHEPATIC TUMOR BURDEN
         </span>
        </p>
        <p class="headingAnchor" id="H1205145379">
         <span class="h2">
          Arterial embolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic arterial embolization is an appropriate option for patients with liver-isolated HCC who are not candidates for resection, transplantation, or ablation, who have relatively preserved liver function (ie, Child-Pugh class A or B cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         )) and no extrahepatic tumor spread, no portal vein tumor thrombus (PVTT) involving the main portal vein or one of its lobar branches  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         ), and a relatively limited intrahepatic tumor burden. For patients with extensive PVTT or a large hepatic tumor burden, systemic therapy may be preferred. There is no consensus definition for the degree of "large intrahepatic tumor burden" at which point a patient would be considered unsuitable for liver-directed therapies. This subject is discussed in more detail elsewhere. (See
         <a class="local">
          'Patient selection and contraindications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
         Arterially directed therapy is also appropriate for "bridging" therapy in a patient awaiting liver transplantation and for selected patients prior to resection of a large HCC, particularly involving the right lobe, in conjunction with portal vein embolization (PVE).
        </p>
        <p>
         The majority of the blood supply for a HCC is derived from the hepatic artery rather than the portal vein. This has led to the development of techniques designed to eliminate the tumor's blood supply by particle embolization and/or to directly infuse cytotoxic chemotherapy into the branch of the hepatic artery that feeds the tumor.
        </p>
        <p>
         Patient selection is critical to the success and safety of transarterial embolization. Benefit from any of these treatments is highly dependent upon tumor-related factors and the severity of the preexisting liver dysfunction.
        </p>
        <p class="headingAnchor" id="H3362464002">
         <span class="h3">
          Is there an optimal embolization approach?
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is marked variability in the types of procedures that have been used for transarterial embolization: bland particle embolization; transarterial chemotherapy, alone or using drug-eluting beads (DEB) and with or without lipiodol; transarterial chemoembolization (TACE), with and without other local therapies (ie, radiation therapy [RT] or tumor ablation); and radioembolization [
         <a href="#rid9">
          9-11
         </a>
         ]. Few randomized trials have directly compared different techniques for hepatic artery embolization, and there is little consensus as to the best approach. For patients in whom hepatic arterial embolization is indicated who do not have portal vein thrombus, we suggest TACE rather than bland embolization or radioembolization. TACE is the only method of transarterial treatment that has been shown in randomized trials to provide a survival advantage compared with supportive care alone for patients with a large unresectable HCC that is not amenable to liver transplantation or local ablation, and it is the most commonly used technique.
        </p>
        <p>
         While additional data from randomized trials are ideally needed to resolve the question of whether TACE plus local ablation is better than either procedure alone, the available evidence supports combined therapy, and at many institutions, TACE plus local ablation (RFA, MWA) is preferred over TACE alone for tumors &gt;2 cm. We agree with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN), which support the use of RFA or MWA plus TACE for intermediate-sized HCC (ie, 3 to 5 cm) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Guidelines from expert groups'
         </a>
         below.)
        </p>
        <p>
         Given the potential for treatment-related toxicity, we reserve the combination of TACE plus RT for patients with portal vein thrombus but preserved unilateral portal blood flow. This subject is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Locoregional treatments'
         </a>
         .)
        </p>
        <p>
         Meta-analyses comparing some of these techniques have had mixed results [
         <a href="#rid13">
          13-16
         </a>
         ].
        </p>
        <p>
         A network analysis comparing the effectiveness of different transarterial therapy techniques in 55 randomized trials with 5763 patients who had preserved liver function and unresectable HCC came to the following conclusions [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All of the embolization strategies achieved a significant survival gain over control treatment (hazard ratio [HR] range 0.42 to 0.76, very low to moderate quality of evidence).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TACE, TACE with DEBs (DEB-TACE), radioembolization, and TACE plus systemic antitumor therapy did not confer any survival benefit over bland embolization alone (moderate quality of evidence, except low quality of evidence for radioembolization).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There was moderate-quality evidence that TACE combined with RT or local ablation achieved the best survival. The estimated median survival was 13.9 months in the control group, 18.1 months with TACE, 20.6 months with DEB-TACE, 20.8 months with bland embolization, 30.1 months with TACE plus RT, and 33.3 months with TACE plus local ablation. Objective response rates were higher when TACE was combined with RT or ablation compared with TACE alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With regards to treatment-related serious adverse effects, radioembolization was the safest treatment (odds ratio [OR] for serious adverse events compared with the control arm 6.35, 95% CI 1.11-5.56). The least safe treatments were TACE plus RT (OR for serious adverse events 53.1) and TACE plus systemic therapy (OR 68.5).
        </p>
        <p>
        </p>
        <p>
         DEB-TACE has become the most commonly used approach to hepatic arterial embolization at many institutions, including those of the authors; bland embolization is not widely accepted. At many institutions, TACE plus local ablation is a preferred approach over TACE alone for tumors &gt;2 cm, although the quality of the data is low. (See
         <a class="local">
          'TACE plus local treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H345068665">
         <span class="h4">
          Guidelines from expert groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines from expert groups differ. TACE, rather than bland embolization alone, is recommended in guidelines from an expert consensus group of the Americas Hepato-Pancreato-Biliary Association (AHPBA) [
         <a href="#rid17">
          17
         </a>
         ]. On the other hand, guidelines from both the NCCN [
         <a href="#rid12">
          12
         </a>
         ] and the American Association for the Study of Liver Diseases (AASLD) [
         <a href="#rid18">
          18
         </a>
         ] recommend chemoembolization, bland embolization, or radioembolization in this setting, with neither group preferentially recommending one form of locoregional therapy over another. (See
         <a class="local">
          'Radioembolization'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2391528792">
         <span class="h3">
          TACE and bland particle embolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         TACE is an appropriate option for patients with a large unresectable or multifocal HCC without main or lobar branch portal vein thrombus that is not amenable to local ablation. TACE is also commonly used as a bridging maneuver in patients awaiting liver transplantation. For most patients who are candidates for resection, preoperative TACE is not indicated. However, TACE may be a complementary procedure prior to PVE if a major liver resection is planned, particularly for a right-sided lesion. (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Chemoembolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17215.html" rel="external">
          "Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance", section on 'Neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
         Bland particle embolization, which relies solely on induction of tumor ischemia by disruption of the blood supply to the tumor, has been utilized successfully for the treatment of both initially unresectable and recurrent HCC [
         <a href="#rid19">
          19-22
         </a>
         ]. However, the majority of the published experience is with TACE, in which transarterial embolization is combined with injection of chemotherapeutic agents, with or without lipiodol (which is sometimes called transarterial oily chemoembolization), into the hepatic artery. Although the evidence from comparative trials is weak [
         <a href="#rid21">
          21,23,24
         </a>
         ] and meta-analyses comparing both procedures have come to differing conclusions [
         <a href="#rid13">
          13-16
         </a>
         ], conventional TACE is the only method of transarterial treatment that has been shown in randomized trials to provide a survival advantage compared with supportive care alone for patients with a large unresectable HCC that is not amenable to liver transplantation or local ablation [
         <a href="#rid23">
          23,25
         </a>
         ], and it is the most commonly used technique for hepatic arterial embolization. (See
         <a class="local">
          'Is there an optimal embolization approach?'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2215765593">
         <span class="h4">
          Patient selection and contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best candidates for TACE are patients with unresectable HCC who have a relatively low intrahepatic tumor burden, without PVTT or extrahepatic spread, and with compensated liver function (ie, no worse than Child-Pugh class A or B cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         )). Baseline liver function seems to be the most important factor predicting survival in patients with unresectable HCC treated with TACE [
         <a href="#rid26">
          26-28
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of
         </strong>
         "
         <strong>
          large" intrahepatic tumor burden
         </strong>
         – There is little consensus as to what constitutes a "large intrahepatic tumor burden," and we prefer that this determination be made individually by the local institution with local expertise.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asia-Pacific consensus guidelines suggest that the following patients be considered "TACE-unsuitable," and better approached with initial systemic chemotherapy [
         <a href="#rid29">
          29,30
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Confluent multinodular type, massive or infiltrative type, simple nodular type with extranodular growth, poorly differentiated type, intrahepatic multiple disseminated nodules;
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Beyond the "up-to-seven" criteria (especially bilobar multifocal HCC), as defined as no more than seven as the sum of the size of the largest tumor [in cm] plus the number of tumors total).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similarly, the updated the BCLC algorithm suggests TACE be restricted to those with "well-defined nodules with preserved portal flow," with systemic chemotherapy for those with "diffuse, infiltrative, extensive bilobar involvement"  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Others use the definition of &gt;50 percent of liver involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extent of portal vein tumor thrombus
         </strong>
         – While all patients with PVTT have been excluded from TACE in the past, patients who have thrombus not involving the main portal vein or its major branches and have preserved unilateral portal blood flow may tolerate the procedure [
         <a href="#rid26">
          26,31,32
         </a>
         ]. However, extensive portal vein occlusion (ie, Vp3, 4  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         )) is associated with a worse outcome with TACE alone than partial or segmental occlusion. Most Western guidelines suggest initial systemic therapy in these cases. On the other hand, more aggressive locoregional anticancer treatments are recommended for selected patients with HCC and PVTT in Chinese, Japanese, South Korean and other Asia-Pacific guidelines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This subject is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Asia-pacific consensus and intermediate-stage HCC'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Absolute contraindications to TACE include absent portal vein flow and decompensated cirrhosis (Child-Pugh class C, or Child-Pugh class B score &gt;8 including jaundice, clinically overt hepatic encephalopathy, refractory ascites, and/or hepatorenal syndrome) [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Relative contraindications include a variety of other factors, including but not limited to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum bilirubin &gt;2 mg/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lactate dehydrogenase &gt;425 units/L
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aspartate aminotransferase &gt;100 units/L
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe comorbidities
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Untreated esophageal varices at high risk of bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior transjugular intrahepatic portosystemic shunting (TIPS)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although several small retrospective case series have demonstrated a good safety profile for TACE among patients with prior TIPS, we suggest that patients be carefully selected and excluded if they have marginal hepatic function. Furthermore, if TACE is undertaken in this setting, selective tumor embolization should be done, if at all possible, in order to minimize hepatic ischemia [
         <a href="#rid35">
          35-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         New clinical scoring systems have been developed to improve patient selection for TACE (eg, the Barcelona Clinic Liver Cancer B subclassification system, the Hepatoma Arterial Embolization Prognostic [HAP] score, the Selection for TransArterial chemoembolization TrEatment score [STATE]) [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, one of these, the HAP score, is derived by assigning one point each to the following factors: albumin &lt;36 g/dL, alpha-fetoprotein (AFP) &gt;400 ng/mL, bilirubin &gt;17 micromol/L (1 mg/dL), and maximum tumor diameter &gt;7 cm [
         <a href="#rid40">
          40
         </a>
         ]. Median survival for individuals undergoing TACE or transarterial embolization with 0, 1, 2, or &gt;2 points prior to the embolization procedure (corresponding to HAP score A, B, C, and D groups) was 27.6, 18.5, 9.0, and 3.6 months, respectively. The performance of this score in patients with larger tumors who are treated with combined TACE plus
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         has not been addressed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H138996162">
         <span class="h4">
          Indications and efficacy
         </span>
        </p>
        <p class="headingAnchor" id="H4129873185">
         <span class="h5">
          Unresectable or multifocal HCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         TACE is most often used for patients with relatively preserved liver function who have unresectable or multifocal HCCs that are not amenable to other local treatments (ie, intermediate stage disease,  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         )). Within this group, there is a wide range of tumor burdens, and the efficacy of TACE is largely dependent on tumor size. The rate of complete tumor response is significantly lower in large (&gt;5 cm) HCCs than in smaller tumors (25 versus 64 percent in one series) [
         <a href="#rid42">
          42
         </a>
         ]. Larger tumor size also is an important prognostic factor for overall survival after TACE [
         <a href="#rid25">
          25,43
         </a>
         ], and because of this, initial systemic therapy may be preferred over locoregional therapies such as TACE for those with a large intrahepatic tumor burden. Unfortunately, there is no well accepted definition for "large intrahepatic tumor burden." This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         .)
        </p>
        <p>
         Efficacy is judged according to local tumor response, duration of response, and the impact on survival. Among patients treated with TACE, approximately 35 to 40 percent of patients will have a ≥25 percent reduction in tumor size [
         <a href="#rid23">
          23,44-47
         </a>
         ]. However, many tumors do not decrease in size even after successful treatment, forcing the use of surrogate markers of response (lack of contrast enhancement on CT or MRI, lipiodol deposition in targeted tumors, decline in AFP) to determine the presence of tumor necrosis and the likelihood that treatment has been beneficial [
         <a href="#rid48">
          48-50
         </a>
         ]. When criteria are used that take into account the area of intratumoral necrosis to estimate the reduction in tumor burden, the rate of objective response is as high as 60 percent [
         <a href="#rid13">
          13,51
         </a>
         ]. When using criteria such as these, sustained response durations of six months or longer are an independent prognostic factor for prolonged overall survival [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
         Despite the widespread acceptance of TACE for unresectable tumors and the suggestion of prolonged survival in multiple phase II studies, it has been difficult to demonstrate that TACE improves overall survival:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least three of five published randomized trials failed to show a survival advantage for TACE compared with a variety of other treatments or conservative management in patients with advanced unresectable HCC [
         <a href="#rid46">
          46,47,53
         </a>
         ]. On the other hand, two relatively small randomized trials have shown a survival advantage for TACE compared with symptomatic treatment alone in selected patients with unresectable HCC and preserved liver function [
         <a href="#rid23">
          23,25
         </a>
         ]. No trial has found a survival advantage for bland embolization alone. (See
         <a class="local">
          'Is there an optimal embolization approach?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Four meta-analyses have addressed the survival benefit of TACE relative to control treatments or bland embolization, with disparate results, likely due to selection bias [
         <a href="#rid13">
          13-16
         </a>
         ]. As an example, in one of the randomized trials comparing TACE with symptomatic treatment alone, TACE significantly prolonged one-year survival (82 versus 63 percent), but survival in the control group was markedly higher than that reported in most treatment studies for advanced HCC [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11113732">
         <span class="h5">
          Prior to resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of uncontrolled series and at least one controlled trial suggest that TACE used prior to an attempt at resection is associated with
         <strong>
          increased
         </strong>
         mortality. Thus, TACE is generally not indicated prior to potentially curative resection. (See
         <a class="medical medical_review" href="/z/d/html/17215.html" rel="external">
          "Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance", section on 'Neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
         One possible exception is in patients who need major resection (eg, right hepatectomy). Preoperative PVE is a valuable adjunct to major liver resection, particularly for right-sided tumors. TACE and radioembolization may be complementary procedures prior to PVE in such patients as they eliminate the arterial blood supply to the tumor and also embolize potential arterioportal shunts that attenuate the effects of PVE in cirrhotic livers. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1850670576">
         <span class="h5">
          Bridging therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver transplantation is a potentially curative option for unresectable HCC. Despite the granting of Model for End-Stage Liver Disease (MELD) exception points for liver transplant candidates with HCC, potential recipients must wait for six months before getting their exception points, and most wait at least an additional six months to a year for a donor organ (unless they are candidates for living donor transplantation). (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Requirements for listing and management while on the wait list'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Living donor transplantation'
         </a>
         .)
        </p>
        <p>
         Several small series have demonstrated the feasibility of TACE prior to orthotopic liver transplantation in patients who are estimated to have a long wait time to transplantation. Despite its uncertain benefit, it remains a common method in many transplant centers to limit the amount of viable tumor at the time of transplantation to help bridge the often prolonged waiting period while a patient is listed and awaiting a donor organ and to improve selection for transplantation based upon tumor biology.
        </p>
        <p>
         In addition, expanded transplantation criteria are now widely accepted for which TACE may be used to downstage larger tumors so that they are within Milan criteria and can be listed for transplant. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Chemoembolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Downstaging through neoadjuvant locoregional therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1248650342">
         <span class="h4">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse effect of TACE, which occurs in 60 to 80 percent of patients, is postembolization syndrome. This consists of varying degrees of right upper quadrant pain, nausea, a moderate degree of ileus, fatigue, fever, and transient elevation of aspartate aminotransferase, alanine aminotransferase, and bilirubin values. Symptoms are usually self-limited, lasting three to four days; full recovery is typical within 7 to 10 days. This may be less common among patients treated with DEBs rather than other methods of embolization, such as gelatin sponge (Gelfoam).
        </p>
        <p>
         Some suggest that tumor necrosis is the main cause [
         <a href="#rid46">
          46,54
         </a>
         ], while more recent reports attribute postembolization syndrome to ischemic damage to normal liver parenchyma [
         <a href="#rid55">
          55,56
         </a>
         ]. Prospective studies are needed to definitively answer the question of whether postembolization syndrome is a side effect to be avoided or an index of the efficacy of the procedure.
        </p>
        <p>
         Although most of the chemotherapy is retained in the liver, there is some systemic exposure, and patients are at risk for nausea, vomiting, and bone marrow depression. The use of DEBs reduces systemic exposure to chemotherapy. (See
         <a class="local">
          'Technique for TACE'
         </a>
         below.)
        </p>
        <p>
         Other, potentially more serious, complications of TACE include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment-induced ischemic damage to the non-tumor-bearing liver is thought responsible for precipitating or exacerbating liver failure. In the meta-analysis cited above, liver failure rates averaged 7.5 percent, but the wide range (0 to 49 percent) likely reflects the heterogeneous patient population [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incidence of hepatic decompensation following TACE is closely related to pretreatment hepatic function [
         <a href="#rid44">
          44,57,58
         </a>
         ]. In a prospective study of 197 sessions of TACE performed in 59 patients with HCC, acute hepatic decompensation developed after 39 sessions (20 percent) and was irreversible in six cases (3 percent) [
         <a href="#rid44">
          44
         </a>
         ]. Patients with irreversible changes were significantly more likely to have higher pre-TACE bilirubin levels, more prolonged prothrombin time, and more advanced cirrhosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More often, hepatic decompensation is reversible, but it may be irreversible. In one study of 251 consecutive patients with HCC and synthetic hepatic dysfunction who underwent 443 TACE procedures, reversible hepatotoxicity developed in 78 patients (31 percent), while irreversible hepatotoxicity developed in 37 patients (15 percent) [
         <a href="#rid58">
          58
         </a>
         ]. Risk factors for irreversible hepatotoxicity were serum bilirubin ≥4 mg/dL, prolonged prothrombin time, serum albumin &lt;2 g/L, serum creatinine &gt;2 mg/dL, large ascites, encephalopathy, or a MELD score ≥20. Notably, these are all patient populations for whom TACE would be considered contraindicated. (See
         <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">
          "Model for End-stage Liver Disease (MELD)"
         </a>
         and
         <a class="local">
          'Patient selection and contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other less common ischemic complications include hepatic abscess (2 percent [
         <a href="#rid59">
          59
         </a>
         ]), acute cholecystitis, and injury to the biliary tract. Bile duct injury (subcapsular biloma, focal stricture of the hepatic or common bile duct, diffuse dilation of the intrahepatic bile ducts) is reported in 0.5 to 2 percent of cases [
         <a href="#rid14">
          14,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastroduodenal ulceration is a recognized complication of TACE (3 to 5 percent) [
         <a href="#rid14">
          14,61
         </a>
         ]. Among the possible explanations are regurgitation of embolizing particles into the right or left gastric artery, the presence of anatomic variants (eg, the right gastric artery too distal to the proper hepatic artery, or an accessory left gastric artery arising from the left hepatic artery), or stress ulcers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal dysfunction (2 percent) is also reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary and cerebral lipiodol embolization are rare but potentially fatal [
         <a href="#rid62">
          62-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An interstitial pneumonia is also described in which radiographic studies are not suggestive of lipiodol retention in the lung [
         <a href="#rid65">
          65
         </a>
         ]. Histologic evaluation (and the fact that most cases occurred after a second injection) raised the possibility of an immunoallergic reaction, with a possible contribution from radiation pneumonitis. However, hypereosinophilia was absent, and glucocorticoid therapy seemed to be of little value. Of note, 12 of the 15 patients reported in this series died, mostly of acute respiratory failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment-related mortality rates from TACE are generally less than 1 percent, but higher rates (approximately 2 to 3 percent) are reported, mostly in patients with very large tumors in whom tumor lysis syndrome develops after TACE [
         <a href="#rid14">
          14,66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3697099562">
         <span class="h4">
          Issues related to HBV reactivation
         </span>
         <span class="headingEndMark">
          —
         </span>
         TACE is a risk factor for reactivation of hepatitis B virus (HBV) infection, and antiviral prophylaxis is recommended for patients who are hepatitis B surface antigen positive. At least some data suggest better outcomes among patients undergoing TACE for HBV associated HCC who are treated concomitantly with nucleoside analogs (
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         , or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ) [
         <a href="#rid67">
          67,68
         </a>
         ]. Issues related to HBV screening and prophylaxis are described separately. (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13754412">
         <span class="h4">
          Technique for TACE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The methodology for TACE varies; the term has been used to refer to the injection of a chemotherapeutic agent into the hepatic artery with or without lipiodol and with or without procoagulant material. Lipiodol is an oily contrast agent that is thought to promote intratumoral chemotherapy retention; however, it probably does not contribute to arterial occlusion [
         <a href="#rid14">
          14,69
         </a>
         ]. While it is thought that chemolipiodolization and embolization have synergistic antitumor activities (the former by inducing high intratumoral concentrations of cytotoxic drugs and the latter by cutting off the blood supply to the tumor), this has never been proven. Worldwide, the most commonly used chemotherapy agents for TACE to treat HCC are
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ; few comparator trials are available [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         In theory, embolization should enhance the effect of chemotherapy by causing metabolically active cell membrane pumps to fail, thereby overcoming drug resistance [
         <a href="#rid71">
          71
         </a>
         ]. However, whether simultaneous or sequential occlusion of the hepatic artery until there is stagnation of blood flow to the tumor results in greater antitumor efficacy than chemotherapy alone has not been proven. Neither the optimal chemotherapeutic agent nor the best embolization method (ie, gelatin sponge [Gelfoam], degradable starch microspheres, polyvinyl alcohol) has been established [
         <a href="#rid14">
          14,72
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-eluting beads
         </strong>
         – Where available, we suggest TACE with drug-eluting beads (DEB-TACE) over conventional TACE. The available data suggest that DEB-TACE is associated with a better side effect profile, although long-term disease-control is likely similar.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A newer approach to TACE, which is being used at most centers, uses DEBs that slowly release chemotherapy, theoretically reducing treatment-related toxicity. In addition, the embolic material (the drug-coated beads) remains within the arteries, in contrast to the lipiodol used in most TACE procedures, which may cross the hepatic sinusoids into the portal venules, causing ischemia and a "dual embolic hit" to the liver parenchyma [
         <a href="#rid73">
          73
         </a>
         ]. DEB-TACE has become the most commonly used approach to hepatic arterial embolization at many institutions, including those of the authors. (See
         <a class="local">
          'Is there an optimal embolization approach?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether DEB-TACE has better efficacy and/or less toxicity as compared with other arterially directed approaches such as standard TACE or TARE is uncertain, as the available data are conflicting:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Results from several small prospective randomized trials and a meta-analysis of seven randomized trials of TACE versus DEB-TACE suggest similar rates of tumor control as with conventional TACE but lower rates of postprocedure pain and serious hepatobiliary toxicity, although follow-up is short in most series [
         <a href="#rid74">
          74-82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         On the other hand, a 2017 network analysis comparing various methods of hepatic arterial embolization concluded that TACE and DEB-TACE were associated with a similar risk of serious adverse effects [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two systematic reviews have come to opposite conclusions about whether DEB-TACE provides superior survival and/or a better side effect profile as conventional TACE [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our view, the best data on comparative toxicity come from the largest randomized trial, the PRECISION V trial, in which conventional TACE using
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (50 to 75 mg/m
         <sup>
          2
         </sup>
         ) was directly compared with DEB-TACE (150 mg of doxorubicin per procedure) in 212 patients with Child-Pugh class A/B cirrhosis and unresectable HCC [
         <a href="#rid75">
          75
         </a>
         ]. The DEB-TACE group had lower rates of treatment-emergent adverse events in the hepatobiliary system (16 versus 25 percent) [
         <a href="#rid76">
          76
         </a>
         ]. The mean maximum postchemoembolization alanine transaminase increase with DEB-TACE was 50 percent less than in the conventional TACE group (p &lt;0.001), and the mean maximum aspartate transaminase increase was 41 percent lower. Furthermore, despite a higher mean total dose of doxorubicin in the DEB-TACE group (295 versus 233 mg), there was a small but statistically significant difference in mean change from baseline in the left ventricular ejection fraction of four percentage points that favored the DEB-TACE group. The incidence of postembolization syndrome was similar between both groups (25 versus 26 percent for DEB-TACE and conventional TACE). On the other hand, treatment-emergent gastrointestinal adverse events occurred more often in patients treated with DEB-TACE (61 versus 45 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          Doxorubicin
         </a>
         DEBs are approved in Europe and Canada (DC Bead, Biocompatibles International, Inc). In the United States, the LC Bead (AngioDynamics, Inc) is commercially available in a variety of sizes and is approved as a medical device. At least some data from a nonrandomized study suggest enhanced efficacy and fewer complications with the smallest particle size (100 to 300 microns) as compared with larger beads [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Irinotecan-eluting beads are beginning to be studied, but only limited data are available, particularly regarding toxicity [
         <a href="#rid86">
          86-88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – The TACE procedure starts with catheterization of the hepatic artery followed by identification of the tumor's feeding vessel. The selectivity of the catheter placement determines the amount of liver embolized. For patients with solitary tumors, the catheter can be placed into a second-order (selective) or third-order (superselective) branch off the right or left hepatic artery [
         <a href="#rid89">
          89
         </a>
         ]. In cases where there are multiple tumors in one lobe, lobar chemoembolization may be needed; however, this is associated with a higher risk of hepatic ischemia and postembolization syndrome. Whenever possible, selective or superselective TACE is preferred. If there is disease involving both lobes, bilateral TACE must be performed sequentially (we generally wait four weeks between procedures). Whole-liver chemoembolization must be avoided because of the potential for serious liver injury and subsequent hepatic decompensation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once the feeding vessel is selected, the chemotherapy is then infused. The choice of chemotherapeutic agent is not standardized, and a variety of agents have been used [
         <a href="#rid90">
          90-96
         </a>
         ]. Some centers use single-agent
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         60 mg plus lipiodol (20 mL), emulsified with water-soluble contrast (10 mL). Others recommend a mixture of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (50 to 100 mg), doxorubicin (20 to 50 mg), and
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         (10 mg), mixed in 10 mL of water-soluble contrast and then emulsified in an equivalent volume of lipiodol [
         <a href="#rid66">
          66,89
         </a>
         ]. Doxorubicin DEBs are used preferentially at many institutions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the event that powdered
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         is not available, equivalent doses of the premixed solution should be used, and an attempt should be made to minimize the overall volume. Regardless of the specific chemotherapy "cocktail" used, the resulting emulsion must be constantly shaken during the infusion, which is then followed by 0.1 to 0.2 mL of 150 to 250 micron polyvinyl alcohol dry particles or gelatin sponge pledgets [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We administer broad-spectrum intravenous antibiotics and antiemetics (a serotonin receptor antagonist,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ) just prior to the procedure. Following TACE, patients are hospitalized until oral intake is adequate and pain is well controlled. In our experience, most patients are discharged within 48 hours of the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most important components of postprocedure care include aggressive hydration (3 L per 24 hours), continued antibiotics (parenteral for 24 hours), prophylaxis against nausea and vomiting (typically
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         , with a serotonin receptor antagonist and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         only as needed), adequate narcotic analgesia (parenteral or oral as needed), and monitoring of electrolytes and liver function tests. Whether prophylactic antibiotics are needed after discharge is controversial. Some recommend five days of oral broad-spectrum coverage [
         <a href="#rid89">
          89
         </a>
         ], while others conclude that prophylactic antibiotics are not routinely necessary but are recommended in patients with biliary reconstruction and impaired liver function [
         <a href="#rid98">
          98
         </a>
         ]. We typically administer five days of an oral broad-spectrum antibiotic (eg,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) after discharge only if the patient developed noninfectious fevers within 24 hours after the procedure. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above, to assess the efficacy of TACE, we typically perform dynamic multiphasic cross-sectional imaging and assay AFP (if initially elevated) initially at four weeks, two to three months later, and then at three-month intervals for at least two years. (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3784360010">
         <span class="h4">
          TACE plus local treatments
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TACE plus local ablation
         </strong>
         – Consistent with consensus-based guidelines from the NCCN [
         <a href="#rid12">
          12
         </a>
         ], we suggest the use of RFA or MWA plus TACE rather than TACE or RFA/MWA alone for intermediate-sized HCC (ie, 3 to 5 cm). Given the potential for treatment-related toxicity, we reserve the combination of TACE plus RT for patients with portal vein thrombus but preserved unilateral portal blood flow. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Locoregional treatments'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Combining local ablation treatment (eg, RFA, MWA, or RT) with TACE can theoretically overcome the limitations of either TACE or ablation when used alone. The chance of achieving complete (&gt;90 percent) necrosis is presumably higher with combined treatment, and some uncontrolled series note better survival with combined treatment over TACE alone [
         <a href="#rid99">
          99,100
         </a>
         ]. However, the quality of the evidence to support combined therapy is generally low [
         <a href="#rid99">
          99
         </a>
         ]. While additional data from randomized trials are ideally needed to resolve the question of whether TACE plus local ablation is better than either procedure alone, the available evidence supports combined therapy, and at many institutions, TACE plus local ablation (RFA, MWA, RT) is preferred over TACE or ablation alone for tumors &gt;2 cm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following data are available to support the benefit and toxicities of combined therapy with TACE plus local ablation:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several randomized trials and at least three meta-analyses have concluded that combined TACE plus RFA improves survival compared with RFA or TACE alone [
         <a href="#rid16">
          16,101-103
         </a>
         ]. In the most recent network analysis, which included 55 trials that both directly and indirectly compared treatments for unresectable HCC, TACE plus RFA was associated with the highest median survival (33 compared with 18.1 months with TACE alone) and had a more favorable rate of serious adverse events compared with TACE alone [
         <a href="#rid16">
          16
         </a>
         ]. However, in all cases, the quality of the evidence was judged to be low. (See
         <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation", section on 'RFA plus TACE'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fewer data are available on the combination of TACE plus MWA. Retrospective single-institution analyses suggest that results with TACE plus MWA are at least as good as those with TACE plus RFA. There are no randomized trials. The superiority of combined treatment over TACE alone was suggested in a retrospective report comparing outcomes in 258 patients with a large solitary or multinodular HCC who underwent TACE plus MWA (n = 92) or TACE alone (n = 166) at a single institution over a four-year period [
         <a href="#rid104">
          104-106
         </a>
         ]. At a median follow-up of 21 months, the one-, two-, and three-year survival rates with TACE plus MWA were 86, 60, and 33 percent; they were 59, 40, and 11 percent for TACE alone. The corresponding recurrence rates were 48, 78, and 95 percent for TACE plus MWA and 75, 96, and 98 percent for TACE alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TACE plus RT
         </strong>
         – Given the potential for treatment-related toxicity, we reserve the combination of TACE plus RT for patients with portal vein thrombus but preserved unilateral portal blood flow. These data are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         RT can be safely delivered to the liver, especially using advanced techniques such as three-dimensional conformal radiation therapy (3D-CRT) and stereotactic body radiation therapy (SBRT) approaches. (See
         <a class="local">
          'External beam RT'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several studies have addressed the benefit of TACE plus RT in the absence of PVTT:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A survival benefit for combined therapy has been suggested in several analyses [
         <a href="#rid16">
          16,99,107,108
         </a>
         ]. As an example, a meta-analysis of 16 trials of TACE with or without external beam RT concluded that combined therapy was significantly better than TACE alone for treatment of HCC [
         <a href="#rid107">
          107
         </a>
         ]. However, there was an increased incidence of gastroduodenal ulcers and elevated levels of alanine transaminase and total bilirubin in patients receiving TACE plus RT compared with those receiving TACE alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, a subsequent Cochrane analysis of nine of these trials concluded that the quality of the evidence to support this conclusion was low to very low, and that additional high-quality trials were needed to assess further the role of RT for unresectable HCC [
         <a href="#rid108">
          108
         </a>
         ]. Combined treatment was associated with a higher risk of elevated total bilirubin and elevated alanine aminotransferase (RR 1.41, 95% CI 1.08 to 1.84).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Likewise, a Cochrane review of eight randomized trials of TACE plus 3D-CRT compared with TACE alone also concluded that combined therapy "may have reduced" all-cause mortality at three years of follow-up, but that the quality of the evidence was low to very low [
         <a href="#rid99">
          99
         </a>
         ]. As was seen in the earlier studies, the proportion of participants with total bilirubin elevation more than twofold higher with combined therapy (RR 2.69, 95% CI 1.34 to 5.40; 172 participants; 2 trials; very low-certainty evidence).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2569596309">
         <span class="h4">
          Retreatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemoembolization procedures using DEBs are typically repeated for each lesion, one month apart. Otherwise, we do not generally repeat the TACE procedure unless there is clear evidence of progressive tumor growth or residual viable tumor in the treated areas. The decision to retreat with TACE for clear-cut disease progression must be individualized and based upon an assessment of tumor response and the hepatic reserve. In addition, the interventional radiologist's assessment of degree of arterial stasis following embolization can help determine the need for future procedures.
        </p>
        <p>
         Overall, less than 2 percent of patients achieve a complete response from a single round of treatment with TACE, but this is variable, with higher response rates in smaller tumors. During follow-up, residual tumor nests recover their blood supply and begin to regrow. This has prompted many centers to repeat the TACE procedure at regular intervals in an attempt to maximize benefit [
         <a href="#rid23">
          23
         </a>
         ]. However, in our view, the benefit of multiple repeated cycles of TACE must be weighed against the adverse effects of repeated procedures, particularly in those with cirrhosis and poor hepatic reserve, and we limit TACE to the minimum number of procedures necessary to control the tumor.
        </p>
        <p>
         Each course of TACE causes some degree of ischemic hepatic damage, which if repeated, has the potential to lead to hepatic decompensation. Excess deaths from deterioration of liver function may counterbalance any prolongation of survival that results from enhanced tumor control [
         <a href="#rid109">
          109
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
         At least two prognostic scoring systems have been developed, based upon post-treatment liver function and radiologic response, to identify patients whose prognosis is too poor after a single TACE session to justify additional TACE treatments [
         <a href="#rid41">
          41,110,111
         </a>
         ]. However, neither of these models has been independently validated.
        </p>
        <p>
         Repeated courses of therapy may not even be possible. TACE causes hepatic artery damage, the likelihood of which is higher in patients with impaired liver function [
         <a href="#rid112">
          112,113
         </a>
         ]. This has the potential to limit the ability to carry out repeated procedures. Even if repeated TACE procedures are feasible, hepatic artery interruption from repeated TACE or arterial dissection can lead to the development of extrahepatic collateralization, which may create an alternative blood supply to the tumor and contribute to treatment failure [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         The definition of "failure of local therapy" for HCC is evolving. The rapidly changing availability of potentially effective and survival-prolonging systemic therapies in HCC has enabled clinicians to offer alternatives to patients who have locally progressive intrahepatic disease, even if they may be eligible for additional liver-directed therapy, such as TACE. Specifically, the acceptance of the toxicity of a risky local procedure in a patient with borderline indications may be tempered by having viable alternative systemic options that did not previously exist. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Treatment at progression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1248650419">
         <span class="h3">
          Radioembolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transarterial radioembolization (TARE) using intra-arterial injection of yttrium-90 (90Y)-labeled glass or resin microspheres induces extensive tumor necrosis with an acceptable safety profile. However, there is no consensus as to the optimal use of this therapy, particularly when and if it should be chosen over TACE for treatment of unresectable HCC. One clinical scenario in which TARE is preferred over TACE is in the setting of an HCC complicated by malignant main or lobar branch portal vein thrombus. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
         Where available, and for appropriately selected patients, newer techniques for superselective TARE such as segmental radioembolization (also called radiation segmentectomy) may provide high rates of local control with less radiation-induced liver disease (RILD) [
         <a href="#rid115">
          115-120
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
         Selection for TARE requires evaluation by a multidisciplinary team. Benefits over other forms of nonsurgical locoregional therapy include relatively low toxicity, the potential to treat patients with significant tumor burden (often in a single setting rather than multiple sessions, as for classic TACE [
         <a href="#rid9">
          9
         </a>
         ]), and relatively limited side effects. However, high cost and certain anatomical constraints (eg, pass through of the radioactive material to the lung in some patients with shunting) limit the utility of this treatment. (See
         <a class="local">
          'Indications and efficacy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1990740176">
         <span class="h4">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         An absolute contraindication to 90Y microsphere TARE is a pretreatment technetium-99m macroaggregated albumin scan that demonstrates the potential for ≥30 Gy radiation to be shunted to the lungs or inadvertent flow to the gastrointestinal tract that cannot be corrected with catheter techniques. Another contraindication is prior RT involving the liver. Otherwise, contraindications to TARE are similar to those for TACE and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically overt hepatic encephalopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biliary obstruction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Child-Pugh class C cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Relative contraindications include bilirubin &gt;2 mg/dL and ascites.
        </p>
        <p>
         Unlike TACE, extensive (including main portal branch,  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         )) vein thrombus or obstruction is not a contraindication to TARE. There is theoretically less arterial ischemia induced by TARE than TACE because of the smaller particle size (32 versus 70 to 300 microns with drug-eluting beads), so the occlusion is more likely to be microvascular than macrovascular, and the resulting tumor necrosis is more likely to be induced by radiation than ischemia. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Benefit of individual therapies'
         </a>
         .)
        </p>
        <p>
         TARE also appears to be safe in patients with prior TIPS [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1990740112">
         <span class="h4">
          Indications and efficacy
         </span>
        </p>
        <p class="headingAnchor" id="H3580538950">
         <span class="h5">
          Prior to resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative PVE is a valuable adjunct to major liver resection, particularly for right-sided tumors. As with TACE, TARE may be a complementary procedure prior to PVE in such patients as it eliminates the arterial blood supply to the tumor and also embolizes potential arterioportal shunts that attenuate the effects of PVE in cirrhotic livers [
         <a href="#rid122">
          122
         </a>
         ]. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540869132">
         <span class="h5">
          Unresectable primary HCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         TARE using 90Y-tagged glass (TheraSphere) or resin (SIR-Spheres) microspheres is safe and effective in patients with unresectable HCC, including those with PVTT. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
         Both products are commercially available in North America, while the resin product is available worldwide. In the United States, 90Y glass microspheres were approved for treatment of unresectable HCC in March 2021, while 90Y resin microspheres are only approved for treatment of colorectal cancer liver metastases.
        </p>
        <p>
         TARE is safe and effective for primary treatment of unresectable HCC [
         <a href="#rid123">
          123-132
         </a>
         ]. The long-term efficacy of 90Y radioembolization is best demonstrated by the following two studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a comprehensive analysis of 291 patients treated with TheraSpheres [
         <a href="#rid130">
          130
         </a>
         ], the World Health Organization response rate (objective bidimensional measurement of perpendicular tumor size) was 42 percent; by EASL criteria (measuring the area of enhancement [
         <a href="#rid51">
          51
         </a>
         ]), 57 percent of patients responded (23 percent complete). (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At a median follow-up of 31 months, the median time to progression was 7.9 months. For patients with Child-Pugh class A and B cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ) without portal vein thrombus, it was 15.5 and 13 months, respectively, while for those with Child-Pugh class A and B cirrhosis and portal vein thrombus, it was 5.6 and 5.9 months, respectively. Median survival time was longer for Child-Pugh class A rather than class B cirrhosis (17.2 versus 7.7 months). Median survival was poor for those patients with Child-Pugh class B cirrhosis and PVTT (2.6 months). The main clinical toxicities were nausea, abdominal pain, fatigue, and transient hyperbilirubinemia; safety results were not reported separately for those patients with and without portal vein thrombus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The multicenter Local radioEmbolization using Glass microspheres for the Assessment of tumor Control with Y-90 (LEGACY) study included 162 consecutively treated patients undergoing TARE with glass microspheres for a solitary HCC ≤8 cm, no worse than Child-Pugh class A cirrhosis, and an Eastern Cooperative Oncology Group performance status of 0 to 1 [
         <a href="#rid133">
          133
         </a>
         ]. TARE served as bridging (neoadjuvant) therapy prior to transplantation in 34 (21 percent) and surgery in 11 (6.8 percent). At a median follow-up of 29.9 months, the confirmed radiographic objective response rate was 72 percent, and the median duration of response was 11.8 months. At 24 months, there were no patients with local progression. Three-year overall survival was 87 percent overall, and 93 percent for those patients undergoing neoadjuvant therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Grade 3 events occurred in 31 patients (19 percent), and no patient experienced RILD despite the use of higher radiation doses than previously administered using radioembolization (median absorbed dose to the treated liver volume was 410 Gy) [
         <a href="#rid134">
          134
         </a>
         ]. Hepatobiliary disorders included ascites in three patients, gallbladder obstruction in one, and portal vein thrombus in one. Serious adverse events occurred in approximately 10 percent of patients, and 5.6 percent were at least possibly related to radioembolization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Largely based on this study, Y90 glass microspheres were approved by the FDA for treatment of unresectable HCC in March 2021.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether results with TARE are better than those that can be achieved with TACE is unclear; the available data are conflicting:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One small pilot randomized trial in 28 patients suggests similar safety and disease control rates with a single session of 90Y radioembolization as with multiple sessions of TACE [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, benefit for TARE over TACE was suggested in a two subsequent small randomized phase II studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the first one, in which 45 patients (out of a potentially applicable pool of 179 potentially eligible patients who met the enrollment criteria) were randomly assigned to a single dose of conventional TACE or 90Y radioembolization [
         <a href="#rid9">
          9
         </a>
         ]. The study was discontinued prematurely because of slow accrual before reaching its goal of 124 patients. At a median follow-up of 17.2 months, the estimated median time to tumor progression with TARE was significantly longer (estimated &gt;26 versus 6.8 months with TACE), but the response to therapy was similar, as was the median survival time censored to liver transplantation (18.6 versus 17.7 months). The small size of this study and the lower-than-expected survival complicate interpretation of these data.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A second small randomized phase II trial directly compared TARE versus TACE with
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         drug-eluting beads in 72 participants with intermediate stage or early stage unresectable HCC not eligible for thermal ablation [
         <a href="#rid135">
          135
         </a>
         ]. In an interim analysis, TARE was associated with a significantly better time to tumor progression (median 17.1 versus 9.5 months), as well as overall survival (30.2 versus 15.6 months), and the safety profile was similar. However, there was an excess of grade 5 adverse event deaths in the DEB-TACE arm that contributed to the divergence in the survival curves (5 of 36 participants versus one of 33 after TARE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A year 2017 network analysis of various hepatic arterial embolization methods concluded that TARE did not confer any survival benefit over bland transarterial embolization alone [
         <a href="#rid16">
          16
         </a>
         ] but that it was the safest option compared with TACE alone or in conjunction with RT or systemic chemotherapy; however, the quality of the evidence was low. (See
         <a class="local">
          'Is there an optimal embolization approach?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, a year 2020 Cochrane analysis concluded that the evidence showing effects of TARE versus TACE in unresectable HCC was highly insufficient [
         <a href="#rid136">
          136
         </a>
         ]; TARE did not seem to differ from TACE in terms of serious adverse events or quality of life, but the certainty of evidence was very low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         None of these analyses included patients treated with superselective radioembolization, which may provide similar or better outcomes as nonselective radioembolization or selective chemoembolization but with less RILD [
         <a href="#rid115">
          115-120
         </a>
         ], and few studies used personalized dosimetry, which improves outcomes as compared with standard dosimetry [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2241121932">
         <span class="h5">
          Bridging therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there are less data than with TACE, TARE is safe and limits disease progression, which may allow patients more time to wait for a donor organ [
         <a href="#rid138">
          138-142
         </a>
         ]. In addition, patients who present with tumors that are beyond the usual transplantation criteria and who do not have malignant portal vein thrombus or extrahepatic disease involvement may be candidates for TARE to downstage the disease to within transplant criteria [
         <a href="#rid143">
          143,144
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Radioembolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Downstaging through neoadjuvant locoregional therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1619265549">
         <span class="h5">
          Expert group recommendations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few high-quality trials have compared TARE with other arterial embolization strategies, and there is a lack of consensus as to the utility of TARE, as illustrated by the differing recommendations from expert groups:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2018 updated clinical practice guidelines from the do not recommend one form of embolization over any other; updated guidelines from the European Association for the Study of the Liver (EASL) state that the subgroup of patients benefitting from TARE needs to be defined [
         <a href="#rid18">
          18,145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines from the NCCN include TACE, bland embolization, and TARE as acceptable treatment modalities for patients with liver-isolated HCC who are not candidates for curative therapy [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An expert consensus group of the AHPBA concluded that TARE could be considered for treatment of HCC in the following scenarios [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Downstaging/bridging to transplantation or resection
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PVTT
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Advanced disease
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H441997277">
         <span class="h4">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications occurring after TARE include the following [
         <a href="#rid146">
          146-149
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A mild postembolization syndrome with fatigue, constitutional symptoms, and abdominal pain (incidence 20 to 70 percent). This is generally less severe than after TACE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic dysfunction due to radioactivity to the surrounding liver parenchyma may manifest as liver failure (attributed to hepatic sinusoidal injury [
         <a href="#rid150">
          150
         </a>
         ]) or RILD (defined as jaundice and ascites appearing one to two months after TARE in the absence of tumor progression or bile duct occlusion [
         <a href="#rid150">
          150-153
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are only limited data on the hepatic parenchymal response to TARE. Among the changes that are described in patients receiving lobar infusions are transient hyperbilirubinemia, ipsilateral hepatic lobar volume decrease with contralateral lobar hypertrophy (a phenomenon that has been termed "radiation lobectomy"), induction of liver fibrosis, and portal hypertension [
         <a href="#rid154">
          154,155
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency and risk factors for development of these adverse effects, and their influence on liver insufficiency have not been well studied. These issues were addressed in a retrospective series of 260 patients with liver tumors (27 with HCC, 67 with colorectal cancer, 25 with neuroendocrine tumors, and 47 with other tumors) treated with TARE, 75 using a standard protocol and 185 using a modified protocol that included
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         (300 mg twice daily for two months starting on the day of radioembolization) plus
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (8 mg daily for one month and 4 mg daily for a second month after TARE) [
         <a href="#rid153">
          153
         </a>
         ]. RILD appeared only in patients with cirrhosis or in noncirrhotic patients who were exposed to systemic chemotherapy within two months before TARE. The incidence of all-stage RILD was reduced from 23 to 5 percent with use of the modified protocol, while the incidence of severe RILD was reduced from 13 to 2 percent. Disease-control rates were identical in patients treated with the standard and the modified protocol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prior exposure of the liver to RT may lead to increased liver toxicity after TARE; use should be restricted to those patients who have had limited or no hepatic exposure to RT [
         <a href="#rid149">
          149,156
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the data are limited, superselective or segmental radioembolization (radiation segmentectomy) may provide similar efficacy as nonselective radioembolization for appropriately selected patients, with a better side effect profile [
         <a href="#rid115">
          115-119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic fibrosis and/or portal hypertension are potential complications [
         <a href="#rid155">
          155,157
         </a>
         ]. These may become more obvious as patients survive longer, and/or the published incidence may underestimate the frequency of these complications due to relatively short follow-up. However, clinically significant manifestations, such as thrombocytopenia or variceal bleeding, are rarely seen following TARE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation pneumonitis is very rare (incidence &lt;1 percent) unless the lung shunt fraction is high, in which case the chance of delivering a high pulmonary dose increases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric or duodenal injury manifests as severe pain during the procedure. The incidence is &lt;5 percent if proper percutaneous techniques are used. Pretreatment angiography is essential to identify and coil embolize variant vessels that may supply the gastrointestinal tract.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular injury, which is most often seen in patients receiving chemotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphopenia [
         <a href="#rid158">
          158
         </a>
         ]; the majority of patients have a &gt;25 percent decrease in lymphocyte count post-treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1439251">
         <span class="h4">
          Response assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, patients treated with TARE have a relatively delayed tumor response; the median time to develop evidence of necrosis (decreased enhancement) and tumor shrinkage is approximately 30 and 120 days, respectively. For this reason, we typically perform the initial radiographic assessment of disease response at approximately three months post-treatment rather than one month later, as is typically done for other forms of nonsurgical local treatment. Postradiation changes are often difficult to distinguish from residual disease complicating post-treatment interpretation. The American College of Radiology's Liver Reporting and Data System (LI-RADS) reporting system is being used to standardize reporting of these post-treatment findings  (
         <a class="graphic graphic_algorithm graphicRef130552" href="/z/d/graphic/130552.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2736811700">
         <span class="h4">
          Retreatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data on retreatment with TARE and no information on the number of safe treatments. At least one study suggests that the risk of potentially fatal TARE-induced liver disease is increased after a second treatment [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2818982038">
         <span class="h3">
          Is there a role for systemic therapy?
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has been a resurgence of interest and enthusiasm for systemic therapy of HCC with the emergence of data showing that the molecularly targeted agents
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         improve survival compared with best supportive care alone; a survival benefit has also been shown for combined
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and combination
         <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">
          durvalumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">
          tremelimumab
         </a>
         compared with sorafenib in the first-line setting, and in the second-line setting for
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         , an immune checkpoint inhibitor;
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         , has also demonstrated noninferiority to first-line sorafenib. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
         For patients with liver-isolated HCC who are eligible for liver-directed nonsurgical therapies, two relevant questions are whether the addition of systemic therapy improves results compared with locoregional therapy alone, and whether initial systemic therapy provides better outcomes than can be achieved with initial liver-directed therapy.
        </p>
        <p class="headingAnchor" id="H356546322">
         <span class="h4">
          Does sorafenib or lenvatinib add benefit to TACE?
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are eligible for TACE, we suggest not adding
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         to TACE. At best, the concomitant use of sorafenib might modestly delay, but not prevent, tumor progression after TACE. Larger, well-designed phase III trials with a survival endpoint are needed before it can be concluded that there is any benefit for the addition of sorafenib to TACE.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
         is a multikinase inhibitor acting on the vascular endothelial growth factor receptor, among others. Findings from the SHARP trial, which showed that sorafenib significantly prolonged survival compared with supportive care alone in patients with advanced HCC, established sorafenib monotherapy as a new reference standard for systemic treatment of advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma", section on 'Sorafenib'
         </a>
         .)
        </p>
        <p>
         It has been hypothesized that administering
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         might be useful to target upregulation of TACE-induced angiogenic factors and thereby improve outcomes from TACE treatment [
         <a href="#rid160">
          160-162
         </a>
         ].
        </p>
        <p>
         However, the benefit of combined therapy over TACE alone has been directly addressed in three randomized phase II trials and two phase III trials, only one of which, presented in abstract form only, suggests benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lack of benefit for post-TACE
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         was shown in an initial phase III trial in which 458 patients with unresectable HCC, Child-Pugh class A cirrhosis, and ≥25 percent tumor necrosis/shrinkage after one or two TACE sessions were randomly assigned to sorafenib (400 mg twice daily) or placebo until progression/recurrence or unacceptable toxicity [
         <a href="#rid163">
          163
         </a>
         ]. The difference in median time to progression in the sorafenib group was not statistically significant (5.4 versus 3.7 months, HR for progression 0.87, 95% CI 0.7-1.09), and there was no difference in overall survival. The median daily dose of sorafenib was only 386 mg, and the median time of administration was only 17 weeks. These factors may have compromised the ability to detect benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, there was no benefit for
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         in a European phase III trial in which 313 patients with unresectable liver-confined HCC were randomly assigned to sorafenib (400 mg twice daily) or placebo; all patients underwent a single DEB-TACE treatment via the hepatic artery two to five weeks following randomization [
         <a href="#rid164">
          164
         </a>
         ]. The trial was stopped prematurely for futility. There was no difference in median progression-free survival (PFS) in the sorafenib and placebo groups (median 238 versus 235 days, respectively, HR 0.99). The median daily sorafenib dose was 660 mg, and the median duration was 120 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two other randomized phase II trials also failed to show clear benefit from the addition of
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , although as with the two phase III trials described above, the duration of sorafenib treatment was short (17 and 21 weeks, respectively) [
         <a href="#rid165">
          165,166
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A subsequent meta-analysis of all three trials [
         <a href="#rid163">
          163,165,166
         </a>
         ], and several other nonrandomized prospective and retrospective reports came to the conclusion that at best, the concomitant use of
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         might modestly delay, but not prevent, tumor progression after TACE [
         <a href="#rid167">
          167
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The only positive randomized phase II trial, the TACTICS trial, randomly assigned 156 Japanese patients with unresectable HCC to TACE alone or to
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         400 mg once daily for two to three weeks prior to TACE and then 800 mg twice daily after TACE was started [
         <a href="#rid168">
          168
         </a>
         ]. In the latest analysis, median PFS, the primary endpoint, was significantly higher with combined therapy (22.8 versus 13.5 months, HR for progression 0.66, 95% CI 0.47-0.94), but the difference in median overall survival was not statistically significant (36.2 versus 30.8 months, HR 0.86, 95% CI 0.61-1.22) [
         <a href="#rid169">
          169
         </a>
         ]. Notably, patients were treated with sorafenib until progression to the point where further TACE treatments were not feasible, and the median duration of sorafenib therapy was 38.7 weeks. The authors postulated that the longer duration of therapy may have contributed to the positive result of this study compared with the other four.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data are also available from a randomized phase II trial comparing TACE plus either
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         ; 71 percent of enrolled patients had PVTT [
         <a href="#rid170">
          170
         </a>
         ]. Compared with TACE plus sorafenib, the combination of TACE plus lenvatinib provided modestly but significantly longer time to tumor progression (median 4.7 versus 3.1 months; HR 0.55; 95% CI 0.32-0.95), a higher objective response rate (53 versus 25 percent), and similar tolerability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These data do not address the question of whether
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         adds benefit to TACE as compared with TACE alone. Additional information is expected from the , which randomly assigns patients with intermediate stage (ie, BCLC stage C) HCC not amenable to curative treatment to TACE with or without lenvatinib and
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         [
         <a href="#rid171">
          171
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Issues specific to the management of patients with HCC complicated by PVTT are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1199354550">
         <span class="h4">
          Embolization with or without systemic therapy versus systemic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the more favorable side effect profile, locoregional forms of therapy, such as TACE and transarterial radioembolization (TARE), may be preferable to systemic therapy alone for initial treatment of patients with locally advanced unresectable HCC without extrahepatic metastases, as long as they are suitable candidates for locoregional treatment.
        </p>
        <p>
         However, for patients with a large intrahepatic tumor burden, or PVTT, systemic chemotherapy using an immunotherapy-based regimen or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         is a preferred approach over locoregional therapy for most patients. Several randomized trials comparing TARE with or without
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         versus sorafenib alone concluded that TARE does not improve survival over sorafenib alone. Furthermore, at least one propensity score-matched analysis concluded that liver function may be better preserved and survival may be longer for patients with a large intrahepatic tumor burden who are treated with first-line lenvatinib compared to TACE [
         <a href="#rid172">
          172
         </a>
         ]. Other options for these patients that are not necessarily preferred include multiagent hepatic arterial infusion chemotherapy (HAIC) with or without sorafenib (where local expertise is available), and lenvatinib plus TACE, based on the results of the phase III LAUNCH trial [
         <a href="#rid173">
          173
         </a>
         ]. The LAUNCH trial was conducted entirely in a Chinese population with a predominance of HBV-related HCC, and whether these results are applicable to other populations is uncertain. These data are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H274148255">
         <span class="h2">
          Hepatic arterial infusion chemotherapy without embolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Where the technical expertise is available, hepatic arterial infusion chemotherapy (HAIC) is an alternative to TACE or initial systemic chemotherapy for patients with large unresectable HCCs or HCC complicated by PVTT. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H125135752">
         <span class="h2">
          External beam RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         External beam RT (EBRT) techniques, including stereotactic body radiotherapy (SBRT) are reasonable options for patients with unresectable HCC who are ineligible for transplantation and are being considered for other liver-directed therapies; patients should have no extrahepatic disease, a limited tumor burden, and relatively preserved liver function (safety data are limited for patients with Child-Pugh class B cirrhosis). However, there are no prospective data comparing SBRT with other forms of locoregional therapy. The choice of SBRT over other liver directed therapies generally depends on institutional expertise and patient preference (SBRT generally requires several visits to plan and execute). Some institutions choose SBRT over embolization for arterially inaccessible tumors, or for individuals with poor baseline kidney function. EBRT may also be considered as an alternative to ablation for those with potentially resectable disease who are inoperable due to extensive comorbidity.
        </p>
        <p>
         Radiation therapy (RT) has historically played a limited role in managing primary HCC because of the limited ability to deliver effective doses without causing toxicity [
         <a href="#rid174">
          174
         </a>
         ]. Early techniques typically used large treatment fields encompassing a substantial portion of the liver, and this inadvertently damaged functional liver parenchyma and caused radiation-induced liver disease (RILD), also called "radiation hepatitis."
        </p>
        <p>
         With the development of three-dimensional conformal radiation therapy (3D-CRT) techniques, higher doses of focal RT can be more safely delivered to the tumor-bearing parts of the liver with less liver toxicity. Technologic developments in delivering more precisely targeted RT (intensity-modulated RT and image-guided approaches, including stereotactic body RT) appear to further improve the risk-to-benefit ratio, although they do not alter the high recurrence rates in other nontreated areas of the liver.
        </p>
        <p class="headingAnchor" id="H2425299089">
         <span class="h3">
          Stereotactic body radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         SBRT is a technique in which a single (sometimes called stereotactic radiosurgery) or a limited number of high-dose RT fractions (typically three to six) are delivered to a small, precisely defined target through the use of multiple nonparallel radiation beams. The beams converge on the target lesion, minimizing radiation exposure to the adjacent normal tissue. This targeting allows treatment in either a single or a limited number of dose fractions.
        </p>
        <p>
         There is growing evidence for the utility of SBRT for unresectable HCC as an alternative to ablation or arterially directed therapy, if the entire disease can be treated without exceeding liver radiation tolerance.
        </p>
        <p>
         The use of SBRT in patients with HCC complicated by PVTT is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3296699799">
         <span class="h4">
          Efficacy and response assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experience with SBRT for primary liver tumors is increasing. A wide variety of dosing and fractionation schedules have been used, with total doses ranging from 24 to 60 Gy over three to six fractions. Overall, local tumor control rates two to three years following SBRT for HCC range from 68 to 95 percent [
         <a href="#rid175">
          175-188
         </a>
         ]. However, in contrast to the encouraging two- and three-year local control rates, two- to three-year PFS rates (which range from 21 to 48 percent) and long-term overall survival rates (which range from 21 to 69 percent) are lower due to out-of-field progression in the untreated parts of the liver [
         <a href="#rid175">
          175,178-182,184-186,189-194
         </a>
         ].
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One of the largest series is a pooled analysis from the University of Michigan and Princess Margaret Hospital of 436 HCC lesions in 297 patients with early to advanced BCLC stage tumors without macrovascular invasion who were not suitable for other standard local therapies; 42 percent had tumors &gt;3 cm [
         <a href="#rid194">
          194
         </a>
         ]. Posttreatment local recurrence rates were low (6.3 and 13.3 percent at one and three years, respectively), and local control was significantly better with lesions &lt;3 cm. However, only approximately 20 percent remained progression-free at 36 months and the one, three, and five-year survival rates were 77, 39, and 24 percent, respectively. Despite the inclusion of patients with Child-Pugh class B or C cirrhosis (22 percent of the total), no patient developed classic RILD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter phase II trial of 74 patients with unresectable HCC (median 2.4 cm, range, 1.1 to 9.9) treated with SBRT (45 to 60 Gy in three fractions) reported two- and three-year local control rates of 97 and 95 percent, respectively, and two- and three-year PFS rates of 48 and 36 percent, respectively. There were only three grade 3 or worse acute liver toxicities within three months of treatment completion.
        </p>
        <p>
        </p>
        <p>
         The place of SBRT in the therapeutic armamentarium for unresectable HCC not eligible for transplant or local thermal ablation is uncertain. There are no prospective data comparing SBRT with other locoregional therapies in this setting [
         <a href="#rid177">
          177,195
         </a>
         ]. SBRT has been generally well tolerated; reported severe toxicity rates are generally less than 10 percent in patients with Child-Pugh class A disease [
         <a href="#rid175">
          175,178-182,196,197
         </a>
         ]. Over the past two decades, a greater understanding of the dose-volume effects of partial-liver RT has enabled radiation therapists to predict the risk of classic RILD associated with a given treatment plan using normal tissue complication probability models [
         <a href="#rid198">
          198,199
         </a>
         ].
        </p>
        <p>
         As with other nonsurgical ablative therapies, response assessment following SBRT for HCC is difficult. (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
         Although 37 to 85 percent of lesions demonstrate a partial or complete response using Response Evaluation Criteria in Solid Tumors  (
         <a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">
          table 2
         </a>
         ) and other conventional response assessment algorithms [
         <a href="#rid175">
          175,176,178-180,189,191,197
         </a>
         ], few studies have examined the relationship between SBRT and other radiographic response criteria based upon visualization of tumor necrosis and/or intratumoral arterial enhancement, as are used to predict outcomes following other treatments for HCC, such as TACE or RFA (ie, LI-RADS treatment response algorithm  (
         <a class="graphic graphic_algorithm graphicRef130552" href="/z/d/graphic/130552.html" rel="external">
          algorithm 2
         </a>
         )). (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
         Complicating matters further, patients treated with SBRT may have a delayed response to therapy on dynamic cross-sectional imaging. Issues related to response assessment in HCC are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/83809.html" rel="external">
          "Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer", section on 'Measuring tumor dimensions versus tumor viability'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2987038608">
         <span class="h4">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our view, SBRT is a reasonable option for selected patients who are being considered for other local treatment modalities and have no extrahepatic disease, have limited tumor burden (ie, the radiation treatment portal will be small), and have relatively preserved liver function. Some centers utilize SBRT for potentially transplantable tumors as "bridging" therapy. There is currently an ongoing
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03960008%3Fterm%3DLiver%2Btransplantation%2Bbridging%2Btherapy%26cond%3DHCC%26draw%3D2%26rank%3D6&amp;token=MfZaa%2Fq7RwgPo7bOXwh7V65d%2FnYNOAqLAc7BYtJJC5Iv8Q6cdBIhrWsSQM8RafjQK6lbw4JFAjGeZ2Tj%2Fd%2BwoewuZGwAV4y9u8oAsUsiLxXiLI2fQsMOozdt7crlKjqh1M%2BLgwXze1LsrEa%2FSgPLL9m8G%2FD%2Fa3L4zZVDVylmccQ%3D&amp;TOPIC_ID=15589" target="_blank">
          international clinical trial
         </a>
         comparing TACE-DEB with SBRT prior to transplantation, evaluating differences in toxicity, outcome, and histologic changes in the explant specimens. (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Stereotactic radiotherapy'
         </a>
         .)
        </p>
        <p>
         Consistent with the dearth of comparative trials, there is a general lack of consensus from expert groups as to the appropriate indications for any form of RT, including SBRT in patients with HCC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2018 clinical practice guidelines from the AASLD do not address the utility of any form of RT alone for treatment of HCC [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consensus-based guidelines from the NCCN list RT (conformal or stereotactic) as an alternative option to ablation or arterially directed therapies for patients with unresectable HCC who are not transplantation candidates or those who are inoperable due to comorbidity [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An expert consensus group of the AHPBA concluded that RT can provide local control for some unresectable HCC lesions, that better RT planning and delivery (eg, hypofractionation, stereotactic treatment, and proton beam therapy [
         <a href="#rid200">
          200
         </a>
         ]) has advanced the ability to escalate the radiation dose to unresectable HCCs without causing undue toxicity, and that strategies combining RT with other therapies merit continued evaluation [
         <a href="#rid17">
          17
         </a>
         ]. However, they did not make specific recommendations as to which patients should be considered for any RT strategy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H245467317">
         <span class="h4">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of RT should be limited to patients with well-compensated liver function (Child-Pugh class A, or early Child-Pugh class B with a score of 7  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         )) who have adequate liver volume outside of the radiation field. Child-Pugh class B patients with a score of ≥8 or Child-Pugh class C patients ought to be treated in a clinical trial or in the bridge-to-transplant setting given the elevated risk of radiation-induced hepatic toxicity in these patients [
         <a href="#rid201">
          201
         </a>
         ].
        </p>
        <p>
         For patients with prior hepatic RT, it is recommended that these patients be evaluated in a tertiary care center with expertise in hepatic RT when considering reirradiation [
         <a href="#rid202">
          202,203
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2425300081">
         <span class="h4">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Minimizing radiation-induced complications depends on careful patient selection and RT treatment planning. Common acute effects include transient fatigue and nausea. Possible long-term effects of radiation to the liver include worsening hepatic function, with associated ascites, hepatomegaly, thrombocytopenia, and elevated liver function tests [
         <a href="#rid204">
          204-208
         </a>
         ]. Rarely, cases of radiation-induced biliary stenosis or death from radiation-induced liver failure have been reported [
         <a href="#rid209">
          209,210
         </a>
         ]. For lesions near the capsule of the liver, there can be transient right upper quadrant pain associated with stretching of the capsule from swelling after treatment. Additionally in situation where SBRT is delivered to the periphery of the liver, care must be taken to minimize radiation to adjacent organs to prevent toxicity (such as radiation pneumonitis, rib fracture, chest-wall pain, bowel or stomach ulceration, or cardiac effects).
        </p>
        <p class="headingAnchor" id="H3074608364">
         <span class="h1">
          PATIENTS WITH LARGE INTRAHEPATIC TUMOR VOLUME OR PVTT
         </span>
        </p>
        <p class="headingAnchor" id="H3231634755">
         <span class="h2">
          Large intrahepatic tumor burden
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some disagree, systemic therapy is a preferred approach over arterially directed therapy alone for patients with a large intrahepatic tumor burden. (See
         <a class="local">
          'Patient selection and contraindications'
         </a>
         above.)
        </p>
        <p>
         Other options for this group include multiagent hepatic arterial infusion chemotherapy (where local expertise is available) or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus TACE, based on results from the phase III LAUNCH trial. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H642382972">
         <span class="h2">
          Portal vein tumor thrombus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal vein tumor thrombus (PVTT) is the most common form of macrovascular invasion in HCC. The development of PVTT is usually accompanied by worsening liver function, vulnerability to spread of metastatic disease, a higher incidence of complications related to portal hypertension, and intolerance for treatment compared with patients without PVTT. The extent of PVTT is a major prognostic factor for HCC; patients with involvement of a lobar branch or the main trunk of the portal vein (ie, Vp3 or Vp4  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         ) have a significantly worse outcome than do those with more proximal involvement. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Definition and extent'
         </a>
         .)
        </p>
        <p>
         For patients with PVTT, options include locoregional approaches (TARE, stereotactic body radiation therapy [SBRT], transarterial chemoembolization [TACE] plus radiation therapy [RT], proton beam irradiation, hepatic arterial infusion chemotherapy [HAIC, where local expertise is available]), initial systemic therapy, or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus TACE.
        </p>
        <p>
         The extent of PVTT may be used to select therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, extensive involvement of a lobar or the main portal vein (ie, Vp3 or Vp4 disease,  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         )) is associated with short survival in patients treated with locoregional therapies; for these patients, initial systemic therapy is preferred over locoregional treatment alone. Another option in this setting, where local expertise is available, in hepatic arterial infusion chemotherapy, with or without
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus TACE, although these approaches are generally not preferred over systemic therapy alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with lesser degrees of PVTT (ie, Vp1 or Vp2), either locoregional therapy or systemic therapy are acceptable options. Decision making must be individualized, and best made in the setting of a multidisciplinary tumor board.
        </p>
        <p>
        </p>
        <p>
         This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H824165514">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119333.html" rel="external">
          "Society guideline links: Hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25897820">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16838.html" rel="external">
          "Patient education: Liver cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H361321233">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of cirrhosis. Treatment options are divided into potentially curative surgical therapies (ie, resection, liver transplantation) and nonsurgical therapies which can be liver-directed or systemic. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Disease extent and hepatic reserve generally dictate the therapeutic approach. An algorithmic approach to treatment is useful to conceptualize the various treatment options that are available, but it may not be applicable in all settings  (
         <a class="graphic graphic_algorithm graphicRef57014" href="/z/d/graphic/57014.html" rel="external">
          algorithm 1
         </a>
         ). Alternative algorithms are available  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Treatment algorithms and general approach to the patient with localized disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We strongly urge that patients with HCC (especially localized HCC) be referred to specialized centers of excellence with multidisciplinary expertise so that the entire range of potentially available treatments can. (See
         <a class="local">
          'Importance of multidisciplinary care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Accurate response assessment for many nonsurgical locoregional therapies requires evaluation of posttreatment residual tumor enhancement, as assessed by the Liver Reporting and Data System (LI-RADS) treatment response algorithm  (
         <a class="graphic graphic_algorithm graphicRef130552" href="/z/d/graphic/130552.html" rel="external">
          algorithm 2
         </a>
         ). In some cases, serial assay of tumor markers such as alpha fetoprotein may also be used. (See
         <a class="local">
          'Assessing response to locoregional therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without PVTT or large intrahepatic tumor burden
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatic arterial embolization is an appropriate option for patients with a unresectable or multifocal HCC who are not candidates for transplantation or thermal ablation, who have no worse than Child-Pugh class A or B cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ), a limited intrahepatic tumor burden, and no extrahepatic tumor spread, vascular invasion, or tumor thrombus involving the main portal vein or one of its lobar branches. It is also appropriate for "bridging" therapy in a patient awaiting liver transplantation and for selected patients prior to resection of a large HCC, particularly involving the right lobe, in conjunction with portal vein embolization. (See
         <a class="local">
          'Arterial embolization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients in whom hepatic arterial embolization is indicated, we suggest transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) rather than bland embolization (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If TACE is chosen, we suggest TACE with drug-eluting beads (DEB-TACE) over conventional TACE given the more favorable side effect profile (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, we restrict TACE to patients with a good performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 3
         </a>
         ), and no vascular invasion, main or lobar branch portal vein thrombus, extrahepatic disease spread, encephalopathy, or biliary obstruction. (See
         <a class="local">
          'Is there an optimal embolization approach?'
         </a>
         above and
         <a class="local">
          'Technique for TACE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with intermediate-sized HCC (ie, 3 to 5 cm), we suggest TACE plus radiofrequency ablation or microwave ablation rather than TACE alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'TACE plus local treatments'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For most patients, we suggest against the addition of
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         to TACE (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Does sorafenib or lenvatinib add benefit to TACE?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients undergoing DEB-TACE, we generally repeat the procedure for each lesion, one month apart. Otherwise, if other techniques are used (eg, conventional TACE), we do not repeat the TACE procedure unless there is clear evidence of tumor progression or residual viable tumor. The decision to retreat with TACE for clearcut disease progression must be individualized and based upon an assessment of tumor response and the hepatic reserve. (See
         <a class="local">
          'Retreatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, there is no consensus as to the optimal use of transarterial radioembolization (TARE) therapy, particularly when and if it should be chosen over TACE for treatment of unresectable HCC. One setting in which TARE is preferred over TACE is HCC complicated by malignant main or lobar branch portal vein thrombus (PVTT). Specific recommendations are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RT techniques such as SBRT are reasonable options for nonsurgically managed patients being considered for other liver-directed therapies who have no extrahepatic disease, a limited tumor burden, and relatively preserved liver function. The choice of SBRT over other liver directed therapies generally depends on institutional expertise and patient preference. (See
         <a class="local">
          'Stereotactic body radiation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with large intrahepatic tumor volume or PVTT
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals with a large intrahepatic tumor burden, initial systemic therapy may be preferred over locoregional therapies such as TACE. Other options include hepatic arterial infusion chemotherapy or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus TACE. There is no well accepted definition for "large intrahepatic tumor burden." (See
         <a class="local">
          'Patient selection and contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Specific recommendations are provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Large intrahepatic tumor burden'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals with extensive PVTT (eg, Vp3 or Vp4,  (
         <a class="graphic graphic_figure graphicRef138754" href="/z/d/graphic/138754.html" rel="external">
          figure 2
         </a>
         )), prognosis is poor with locoregional treatment, and initial systemic chemotherapy is preferred. For less extensive PVTT, either locoregional therapy or systemic therapy may be chosen, if the patient is otherwise a candidate for locoregional treatment. Specific recommendations are provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014; 21:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serper M, Taddei TH, Mehta R, et al. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017; 152:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry M, McGinty KA, Mervak B, et al. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology 2020; 294:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kielar A, Fowler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018; 43:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaffer KM, Parikh MR, Runge TM, et al. Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation. Liver Transpl 2015; 21:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslam A, Do RKG, Kambadakone A, et al. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulin M, Guiu B. Chemoembolization or Bland Embolization for Hepatocellular Carcinoma: The Question Is Still Unanswered. J Clin Oncol 2017; 35:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013; 105:59.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; :CD004787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0184597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz RE, Abou-Alfa GK, Geschwind JF, et al. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010; 12:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Covey AM, Maluccio MA, Schubert J, et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 2006; 106:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanks BA, Suhocki PV, DeLong DM, et al. The efficacy and safety of transarterial chemoembolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26S:ASCO #236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KT, Do RK, Gonen M, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol 2016; 34:2046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008; 112:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudo M, Han KH, Ye SL, et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020; 9:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Dig Dis 2015; 33:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013; 30:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura JT, Rilling WS, White SB, et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford) 2015; 17:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Zhang H, Zhao H, et al. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol 2014; 20:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo YC, Kohi MP, Naeger DM, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013; 36:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang JW, Kim JH, Ko GY, et al. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha Y, Shim JH, Kim SO, et al. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol 2014; 29:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24:2565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 2014; 61:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol 2013; 24:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27:5734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castrucci M, Sironi S, De Cobelli F, et al. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom Imaging 1996; 21:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zhang M, Chen M, et al. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2018; 1:e183213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doffoël M, Bonnetain F, Bouché O, et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer 2008; 44:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castells A, Bruix J, Ayuso C, et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigmore SJ, Redhead DN, Thomson BN, et al. Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury? Br J Cancer 2003; 89:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paye F, Farges O, Dahmane M, et al. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 1999; 86:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garwood ER, Fidelman N, Hoch SE, et al. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HK, Chung YH, Song BC, et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001; 32:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 2005; 11:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu GC, Perng WC, Chen CW, et al. Acute respiratory distress syndrome after transcatheter arterial chemoembolization of hepatocellular carcinomas. Am J Med Sci 2009; 338:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JT, Heo SH, Choi SM, et al. Cerebral embolism of iodized oil (lipiodol) after transcatheter arterial chemoembolization for hepatocellular carcinoma. J Neuroimaging 2009; 19:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok PC, Lam TW, Lam CL, et al. Rare pulmonary complications after transarterial chemoembolisation for hepatocellular carcinoma: two case reports. Hong Kong Med J 2003; 9:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jouneau S, Vauléon E, Caulet-Maugendre S, et al. ¹³¹I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases. Chest 2011; 139:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown DB, Chapman WC, Cook RD, et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol 2008; 190:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyoda H, Kumada T, Tada T, et al. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012; 23:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrillo RP. Reactivated hepatitis B due to medical interventions: the clinical spectrum expands. Antivir Ther 2011; 16:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aramaki O, Takayama T, Moriguchi M, et al. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. Eur J Cancer 2021; 157:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruskal JB, Hlatky L, Hahnfeldt P, et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13:S211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh D, Shin SW, Park HC, et al. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. Cancer Res Treat 2015; 47:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197:W562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrer Puchol MD, la Parra C, Esteban E, et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao S, Yang Z, Zheng Z, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prajapati HJ, Dhanasekaran R, El-Rayes BF, et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie ZB, Wang XB, Peng YC, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res 2015; 45:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang B, Liang J, Qu Z, et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One 2020; 15:e0227475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prajapati HJ, Xing M, Spivey JR, et al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR Am J Roentgenol 2014; 203:W706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Metzger T, Robbins K, et al. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 2010; 12:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown DB, Geschwind JF, Soulen MC, et al. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006; 17:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JW. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatogastroenterology 1998; 45 Suppl 3:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994; 8:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinchet JC, Ganne-Carrie N, Beaugrand M. Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology 1998; 45 Suppl 3:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuen MF, Ooi CG, Hui CK, et al. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003; 97:2776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart K. Chemoembolization in the management of liver tumors. Oncologist 2003; 8:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plentz RR, Lankisch TO, Bastürk M, et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005; 20:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu L, Zeng J, Wen Z, et al. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev 2019; 2:CD012244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           English K, Brodin NP, Shankar V, et al. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2020; 3:e2023942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni JY, Liu SS, Xu LF, et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013; 139:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012; 57:3026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang YJ, Chen MS, Chen Y, et al. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA Netw Open 2021; 4:e2126992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsburg M, Zivin SP, Wroblewski K, et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol 2015; 26:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, et al. Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2017; 18:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng L, Li HL, Guo CY, Luo SX. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas. Korean J Radiol 2018; 19:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol 2015; 1:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017; 3:CD011314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57:2261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adhoute X, Penaranda G, Raoul JL, Bourlière M. Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''. J Hepatol 2015; 62:1442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sueyoshi E, Hayashida T, Sakamoto I, Uetani M. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2010; 195:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeda N, Osuga K, Mikami K, et al. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 2008; 26:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HC, Chung JW, Lee W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25 Suppl 1:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padia SA, Kwan SW, Roudsari B, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014; 25:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra A, Liu DM, Talenfeld AD. Radiation Segmentectomy and Radiation Lobectomy: A Practical Review of Techniques. Tech Vasc Interv Radiol 2019; 22:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman DM, Titano JJ, Korff RA, et al. Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. J Vasc Interv Radiol 2018; 29:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology 2018; 287:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahue LA, Kulik L, Baker T, et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013; 24:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao X, He N, Sun J, et al. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J (Engl) 1999; 112:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokabi N, Camacho JC, Xing M, et al. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer 2015; 121:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021; 48:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhondt E, Lambert B, Hermie L, et al. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology 2022; 303:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1:CD011313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi Sandri GB, Ettorre GM, Giannelli V, et al. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017; 2:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radunz S, Treckmann J, Baba HA, et al. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017; 22:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol 2014; 61:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol 2016; 1:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabr A, Kulik L, Mouli S, et al. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology 2021; 73:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reguera-Berenguer L, Orcajo-Rincón J, Rotger-Regí A, et al. Downstaging of bilobar hepatocellular carcinoma after radioembolization with 90Y microspheres as a bridge to liver transplantation. Rev Esp Med Nucl Imagen Mol 2017; 36:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for the Study of the Liver. Electronic address:
           <span class="__cf_email__" data-cfemail="f99c988a95969f9f909a9cb99c988a95969f9f909a9cd79c8c">
            [email protected]
           </span>
           , European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol 2014; 4:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 2008; 53:2556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam MG, Abdelmaksoud MH, Chang DT, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 87:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayav A, Habib N, Jiao LR. Portal hypertension secondary to 90Yttrium microspheres: an unknown complication. J Clin Oncol 2005; 23:8275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr BI, Metes DM. Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012; 82:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam MG, Louie JD, Iagaru AH, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2013; 36:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012; 56:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erhardt A, Kolligs F, Dollinger M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol 2014; 74:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 2015; 136:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012; 17:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Chen H, Wang M, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One 2014; 9:e91124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69:1492.
          </a>
         </li>
         <li class="breakAll">
          Kudo M, Ueshima K, Ikeda M, et al. TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC) (abstraact).  J Clin Oncol 39, 2021 (suppl 3; abstr 270). Abstract available online at https://meetinglibrary.asco.org/record/194239/abstract (Accessed on January 25, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer 2021; 127:3782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llovet JM, Vogel A, Madoff DC, et al. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol 2022; 45:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel) 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng Z, Fan W, Zhu B, et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol 2023; 41:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell AH, Clyde C, Wasserman TH, et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993; 27:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol 2016; 34:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118:5424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81:e447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012; 84:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol 2012; 7:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honda Y, Kimura T, Aikata H, et al. Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatogastroenterology 2014; 61:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014; 53:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013; 8:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohri N, Tomé WA, Méndez Romero A, et al. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys 2021; 110:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apisarnthanarax S, Barry A, Cao M, et al. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2022; 12:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2022; 128:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi BO, Jang HS, Kang KM, et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006; 36:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012; 118:3191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang WI, Bae SH, Kim MS, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy. Cancer 2020; 126:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SM, Lim YS, Park MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 2013; 8:e79854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew AS, Atenafu EG, Owen D, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020; 134:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol 2018; 36:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka Y, Nakazawa T, Komori S, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J Gastroenterol Hepatol 2014; 29:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng JC, Liu HS, Wu JK, et al. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2005; 62:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush DA, Volk M, Smith JC, et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer 2023; 129:3554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanciano R, Lamond J, Yang J, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol 2012; 2:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seol SW, Yu JI, Park HC, et al. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J 2015; 33:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanuki N, Takeda A, Oku Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 2015; 45:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002; 54:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osmundson EC, Wu Y, Luxton G, et al. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys 2015; 91:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi S, Kimura T, Kenjo M, et al. Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 2014; 44:E273.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15589 Version 73.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34801630" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24318095" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283421" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31845843" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780679" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25559230" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25786913" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33200013" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27575820" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28056196" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chemoembolization or Bland Embolization for Hepatocellular Carcinoma: The Question Is Still Unanswered.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23150720" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23150720" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12540794" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17103105" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21412886" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28934265" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20590905" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130846" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : AASLD guidelines for the treatment of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9756073" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Particle embolization for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16596622" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23449352" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The efficacy and safety of transarterial chemoembolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12049862" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26834067" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11981766" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16371532" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18008352" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17057003" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32647629" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26488473" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8513208" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hepatic chemoembolization: safety with portal vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20839057" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25681552" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Transarterial chemoembolization: modalities, indication, and patient selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24436512" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Chemoembolization of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172137" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25297389" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23864021" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22547388" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24224567" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857958" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25016222" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23428355" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173160" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920537" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9620330" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7708069" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9696501" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805671" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8875869" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10954453" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11592607" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646226" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18242076" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7665860" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14562011" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10100782" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cytolysis following chemoembolization for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8539401" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23008091" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287508" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11319315" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15770737" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19826242" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Acute respiratory distress syndrome after transcatheter arterial chemoembolization of hepatocellular carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19496902" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cerebral embolism of iodized oil (lipiodol) after transcatheter arterial chemoembolization for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14660814" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Rare pulmonary complications after transarterial chemoembolisation for hepatocellular carcinoma: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947651" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : ¹³¹I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18287429" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22265248" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22024509" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Reactivated hepatitis B due to medical interventions: the clinical spectrum expands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239480" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34563992" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8280994" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12354839" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Chemoembolization of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25578056" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19937027" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19908093" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940527" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734423" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21295802" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21849247" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23282741" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23375519" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24937669" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25388603" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32074102" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25415737" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20661569" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20495642" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19886993" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16517767" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9730381" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Transcatheter arterial chemoembolization of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8003400" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Chemoembolization of hepatic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7516263" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10392950" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9730382" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Intra-arterial chemoembolization in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767090" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530495" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Chemoembolization in the management of liver tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9407353" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Non-surgical treatment of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15955232" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30776082" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33151315" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23292073" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22585384" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34570206" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25534635" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28240516" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29520181" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26182200" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28267205" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : External beam radiotherapy for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8661839" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23316013" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25678389" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20566824" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509720" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227494" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20421150" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24691943" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24837982" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31079710" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Radiation Segmentectomy and Radiation Lobectomy: A Practical Review of Techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29169782" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29688155" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23273699" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23811303" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20066715" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9486608" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11593513" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11037997" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17048240" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16904840" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18989675" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766639" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25847227" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25443863" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33739462" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32749512" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35258371" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31978267" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33166497" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29264436" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408731" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24681342" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28799575" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32416631" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28268101" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Downstaging of bilobar hepatocellular carcinoma after radioembolization with 90Y microspheres as a bridge to liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19552767" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29628281" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440457" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Biliary sequelae following radioembolization with Yttrium-90 microspheres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19640737" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16371529" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25120955" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Side effects of yttrium-90 radioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260156" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Liver disease induced by radioembolization of liver tumors: description and possible risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18003987" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19157721" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23225191" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Prognostic factors and prevention of radioembolization-induced liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19357924" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18231857" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23849697" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16278485" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21601995" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23354961" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Safety of repeated yttrium-90 radioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22314421" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173458" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25099027" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21664811" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28648803" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22334456" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26809111" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24651044" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31801872" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31801872" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34237154" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35119481" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31370183" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35921605" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8365932" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20813065" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23547075" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26628466" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22570179" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21645977" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Stereotactic body radiotherapy for primary hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22342300" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23050794" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24895789" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23962244" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24160944" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29395629" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Local Control After Stereotactic Body Radiation Therapy for Liver Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30773180" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34688956" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34847255" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172187" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16520355" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22025126" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31747476" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24255719" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32460180" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29328861" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23869689" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21960321" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12095546" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Analysis of radiation-induced liver disease using the Lyman NTCP model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15990021" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37503907" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24906626" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22645716" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26756027" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15752895" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Local radiotherapy for patients with unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5327788" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : The human liver after radiation injury. A form of veno-occlusive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24976460" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182985" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Dose-response relationship in local radiotherapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16541431" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Radiation therapy for hepatocellular carcinoma: from palliation to cure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25659885" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24102845" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
